Licensing Opportunities: Neurology

Published by	Decision Resources, Inc.
Published	April, 2010	Product code	118670
Content info	35 Pages
Price	US $ 4600 PDF by E-mail (Global License)

Introduction
Related Reports

Licensing Opportunities: Neurology published by Decision Resources, Inc. in April, 2010. This report consists of 35 Pages and the price starts from US $ 4600.

Introduction

Abstract

Introduction:

The future of drug discovery and development will be modeled on extensive cooperation and collaboration between multiple academic, government, nonprofit, and industry stakeholders - not on the individual R&D silos that pharmaceutical companies have instituted until very recently. Neurological drug discovery and development will benefit significantly from this new approach, given the intractable and complex nature of neurological diseases. Large and small pharmaceutical and biotech companies are turning to one another as sources of needed licensing, partnering, or acquisitions. To understand the landscape and dynamics of the neurology industry, we looked at different types of companies that are active in the neurology therapy area, analyzed their drug development and commercialization activities, and explored potential opportunities.

Questions Answered in This Report:

In 2008, the central nervous system (CNS) market was the second largest therapy market (after the top-ranked cardiovascular market), totaling $87 billion in worldwide pharmaceutical sales. Who were the major players in this market in 2008? Who will be the major players in 2015? What are the major brands and their worldwide sales? What late-stage drugs that will launch soon are expected to achieve significant commercial success?
Partnering and inlicensing are becoming a way of life for small and large companies alike. Which Big Pharma, Midsize Pharma, and small biotech/neuroscience companies are active in neurology? What are the major brands in company neurology portfolios? What neurology agents are in development in the pipelines of these companies?
Many opportunities exist for generics competitors to challenge neurology patents and bring therapeutic equivalents to market as soon as they can. Which eight neurology brands recently went off patent, and which generics companies have received FDA approval to market generic equivalents? What is the status of authorized neurology generics and pay-for-delay deals for neurology drugs?

Scope:

Expert commentaries: Peter Wittner of Interpharm Consultancy on the activities of midsize European pharma companies and Big Pharma companies that are active in neurology drug markets and neurology R&D; insights on the Alzheimer' s disease market from Matthew Winton, Ph.D., a Decision Resources analyst specializing in central nervous system diseases.
Primary data: Results from a survey of 29 U.S. neurologists on the impact of Dimebon' s clinical trial failure on the Alzheimer' s disease drug market; forecasted market size and sales of neurology brands from Decision Resources analysts.
Neurology markets: Major players; brands with worldwide sales of more than $500 million; market size; projected growth of specific disease market segments; maturation of Sanofi-Aventis' s neurology portfolio.
Neurology pipelines: Competition from drugs soon to launch; recent late-stage failures; leading company pipelines by number of agents by disease; soon-to-launch drug candidates with potential worldwide sales of more than $300 million in 2015; vaccines in development for Alzheimer' s disease.
Major neurology players: Analysis of the neurology interests of more than 15 small neuroscience/ biotechnology companies, 13 Midsize Pharma companies, 20 generics companies, and 10 Big Pharma companies; generics companies; European and Japanese pharmaceutical companies active in neurology; marketed neurology drugs; neurology drug candidates in development; existing partners; companies looking for partners.
Generics companies: Authorized generics for certain neurology drugs; pay-for-delay deals; patent litigation settlement deals; more than 40 generics companies approved to market 8 recently expired neurology brands.
Outlook: Five insights on opportunities in the neurology therapy area; an emerging model of extensive cooperation and collaboration in basic research, drug discovery, and development.

Mentioned in This Report:

Abbott Laboratories
AC Immune
Accord Healthcare
Acorda Therapeutics
Actavis
Actelion
Addex Pharmaceuticals
Affiris
Alembic
Allon Therapeutics
Almirall
Alpharm
Amneal Pharmaceuticals
Anchen Pharmaceuticals
Apotex
App Pharmaceuticals
Astellas Pharma
Aurobindo Pharma
Avineuro Pharmaceuticals
Barr Laboratories
Bayer
Bayer Schering Pharma
Bedford Laboratories
Bejing Yabao
Biogen Idec
Boca Pharma
Boehringer Ingelheim
Britannia Pharmaceuticals
Centre Hospitalier Universitaire d' Angers
Cephalon
CHDI Foundation
Chiesi Farmaceutici
Cilag
Cipla
Cobalt Laboratories
CorePharma
CSL
Cypress Pharmaceutical
Cytos Biotechnology
D-Pharm
Dainippon Sumitomo
Dr. Reddy' s Laboratories
Edison Investment Research
Eisai
Elan
Eli Lilly
European Medicines Agency
Food and Drug Administration (FDA)
Forest Laboratories
Fumapharma
Genentech
Genzyme
GlaxoSmithKline
GlaxoSmithKline Biologicals
Glenmark Generics
GW Pharmaceuticals
H. Lundbeck
Huahai US
Impax Laboratories
Intellect Neurosciences
Interpharm Consultancy
Invagen Pharmaceuticals
Janssen
JHP Pharmaceuticals
Johnson & Johnson
Kyowa Hakko Kirin
Lupin Therapeutics
Meda
Medivation
Memory and Aging Center, University of California, San
Francisco (UCSF)
Menarini
Merck & Co.
Merck KGaA
Merck Serono
Merz
Mitsubishi Tanabe Pharma
Mutual Pharmaceutical
Mylan
Neurocrine Biosciences
NeuroNova
NeuroSearch
Newron Pharmaceuticals
New York Academy of Sciences
Novartis
NuPharm
Orchid Healthcare
Ortho Biotech
Otsuka Pharmaceutical
Ovation Pharmaceuticals
Par Pharmaceutical
PDL BioPharma
Pfizer
Pharmaceuticals and Medical Device Agency (PMDA)
Phytopharm
Prana Biotechnology
Prasco Laboratories
Ranbaxy Laboratories
Raptor Pharmaceuticals
Recordati
Roche
Roche Venture Fund
The Rockefeller University
Roxane Laboratories
Saegis Pharmaceuticals
Sandoz
Sanofi-Aventis
Sanofi-Synthelabo
Servier
Shire
Silarx
SK Bio Pharmaceuticals
Solco Healthcare
Spectrum Pharmaceuticals
SR-One
State University of Moscow
Sun Pharmaceutical Industries
Sygnis Pharma
Taro Pharmaceuticals
TauRx Therapeutics
Teva Pharmaceutical Industries
Tolmar
Torrent Pharmaceuticals
Torrex Chiesi Pharma
TorreyPines Therapeutics
U.S. Court of Appeals for the District of Columbia
U.S. District Court for the District of Delaware
U.S. Patent and Trademark Office
UCB
Unichem Laboratories
United Biomedical
Upsher Smith
U.S. Federal Trade Commission (FTC)
Vernalis
Vintage
Wanbang Biopharmaceuticals
Watson Laboratories
Wockhardt
Wyeth
XenoPort
YungJin Pharmaceuticals
Zogenix
Zydus Pharmaceuticals

ZymoGenetics

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Looking for Opportunities
Forecast Market Growth, 2008 to 2015
Major Brands in Neurology Markets
Near-Term Competition from Drugs in Late-Stage Development
Late-Stage Clinical Development Setbacks
Small Company R&D Activities in Neurology
- AC Immune
- Addex Pharmaceuticals
- Allon Therapeutics
- Avineuro Pharmaceuticals
- D-Pharm
- Intellect Neurosciences
- Neurocrine Biosciences
- NeuroNova
- NeuroSearch
- Newron Pharmaceuticals
- Phytopharm
- Prana Biotechnology
- Raptor Pharmaceuticals
- Sygnis Pharma
- TauRx Therapeutics
Potential Partners
- Big Pharma
- Midsize European Pharma
  - Almirall
  - Chiesi Farmaceutici
  - H. Lundbeck
  - Merck KGaA
  - Recordati
- Midsize Japanese Pharma
  - Astellas Pharma
  - Dainippon Sumitomo
  - Eisai
  - Kyowa Hakko Kirin
  - Mitsubishi Tanabe Pharma
- Midsize Biotech
  - Biogen Idec
  - Cephalon
  - Genzyme
Generic Opportunities
- Generics Companies Manufacturing and Selling Neurology Drugs
- Near-Term Generics Opportunities
- Agreements Between Pharma and Generics Companies
Outlook

Expert Commentaries

Peter Wittner, principal, Interpharm Consultancy
- Potential Partners: Big Pharma
- Potential Partners: Midsize European Pharma

Matthew Winton, Ph.D., Decision Resources analyst specializing in central nervous system diseases
- Assessing the Impact of Dimebon' s Clinical Trial Failure on the Alzheimer' s Disease Drug Market

Tables

1. Neurological Brands with Worldwide Sales of $500 Million or More, 2008 and 2015
2. Neurological Drug Candidates with Potential Worldwide Sales of $300 Million or More, 2015
3. Vaccines in Development for Alzheimer' s Disease
4. Generics Companies with FDA Approval to Market Select Neurology Drugs
5. Authorized Generics in the United States for Select Neurology Drugs
6. Neurology: Major Players in R&D or with Marketed Drugs